Cosium 10 mg (Tablet)

Unit Price: ৳ 5.00 (10 x 10: ৳ 500.00)

Strip Price: ৳ 50.00

Medicine Details

Category	Details
Generic	Clobazam
Company	Acme laboratories ltd

Treats acute and chronic anxiety states
Relieves symptoms of anxiety, tension, restlessness, excitement, irritability, and sleep disturbances
Addresses psychovegetative and psychosomatic disorders
Adjunctive therapy for patients with depression or anxiety associated with depression
Adjunctive therapy for patients with schizophrenia or other psychotic illnesses
Functional for patients with epilepsy who are not adequately stabilized with their anticonvulsant monotherapy

Binds at distinct binding sites associated with the chloride ionopore at the post-synaptic GABA receptor
Increases the duration of time for which the chloride ionopore is open
Enhances the post-synaptic inhibitory effect of GABA
Leads to hyperpolarization and stabilization of the membrane
Operates in various locations in the CNS (limbic, reticular formation)

Initial dose usually 20 mg clobazam daily for adults and adolescents over 15 years of age
Maintenance dose of 10 to 15 mg clobazam daily for elderly patients
Daily dose of 5 to 10 mg clobazam for children from 3 to 15 years of age
Gradual dose increments under careful observation for elderly and pediatric patients
Timing of doses including larger portion taken in the evening
Duration of treatment must be as short as possible, not exceeding 8 to 12 weeks
Treatment must not be extended without re-evaluation of the patient's status using special expertise

Concomitant consumption of alcohol can increase the bioavailability of Cosium by 50%
Mutually potentiating effect with central nervous system depressant drugs when administered in higher doses
Concomitant use with opioids increases the risk of sedation, respiratory depression, and coma
Dosage adjustment necessary when administered simultaneously with anticonvulsants in the treatment of epilepsy
Possible euphoria enhancement if used concomitantly with narcotic analgesics
Effects of muscle relaxants and nitrous oxide may be enhanced

Hypersensitivity to clobazam or any of the excipients of Clobazam
Myasthenia gravis
Severe respiratory insufciency
Sleep apnoea syndrome
Severe impairment of liver function
Breastfeeding women
Children between the ages of 6 months and 3 years, except in exceptional cases for anticonvulsant treatment where there is a compelling indication

Decreased appetite
Irritability, aggression, restlessness, depression, drug tolerance, agitation
Somnolence, sedation, dizziness, disturbance in attention, slow speech, dysarthria
Headache, tremor, ataxia
Dry mouth, nausea, constipation
Rash, photosensitivity reaction, urticaria
Muscle spasms, muscle weakness
Fatigue, slow response to stimuli, hypothermia

Not recommended during the first trimester of pregnancy
Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Must not be used in breastfeeding women
Clobazam crosses the placenta
Neonatal respiratory depression, sedation signs, hypothermia, and hypotonia may occur in the newborn

Closely monitor for signs or symptoms of serious skin reactions, especially during the first 8 weeks of treatment
Respiratory function must be monitored especially in patients with chronic or acute respiratory insufficiency
Cautious use in patients with myasthenia gravis
Increased responsiveness and susceptibility to adverse effects in patients with impairment of renal or hepatic function
Recommended dose reduction in elderly patients
Consideration for the possibility of a decrease in anticonvulsant efficacy in the course of treatment
Increased risk of fall in elderly patients